Asia Pacific Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and

Asia Pacific Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

The Asia Pacific pulmonary arterial hypertension market is expected to grow from US$ 1,531.47 million in 2022 to US$ 2,236.62 million by 2028; it is estimated to grow at a CAGR of 6.5% from 2022 to 2028.

Rising Clinical Trials for Drug Development to Treat Pulmonary Arterial Hypertension to Fuel Asia Pacific Pulmonary Arterial Hypertension Market in Coming Years

Growing advancements in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease are supporting the development of PAH therapies. With the growing knowledge, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in the treatment of other forms of pulmonary hypertension and combination therapies. This is likely to be the standard for clinical trials in the coming years. Rising clinical trials for drug development to treat pulmonary arterial hypertension are expected to fuel the Asia Pacific pulmonary arterial hypertension market during the forecast period.

Asia Pacific Pulmonary Arterial Hypertension Market Overview

The Asia Pacific pulmonary arterial hypertension market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest market share in 2021, and India is expected to exhibit significant market growth during the forecast period. In China, a large-scale nationwide pulmonary arterial hypertension (PAH) registry—including over 2,000 patients and detailed data on prescription patterns and treatment—was published in 2022, which reported that congenital heart disease-related PAH (45.2%) was reportedly the most common type of PAH in the country. However, the accessibility of PAH drugs in China remains poor, with only a few cities including the costs of drugs in their medical insurance. Hence, financially unstable patients suffering from PAH do not complete the entire treatment period.

Further, the presence of key players and rising pulmonary arterial hypertension drug development in the country are boosting the market in China. Manufacturers focus on expanding their strategic global presence and specialized expertise with exclusive technological capabilities, leading to better PAH drug availability in China. For instance, Toray and Shenzhen Main Luck Pharmaceuticals are preparing to launch Careload in early 2023. In September 2022, Toray Industries, Inc. announced that it had received approval from the National Medical Products Administration (NMPA) in China for Careload tablets to treat pulmonary arterial hypertension. Similarly, in February 2021, Aerami Therapeutics, Inc. announced the signing of an exclusive license and development agreement with Hangzhou Chance Pharmaceuticals Co. Ltd. to develop and commercialize Aerami’s drug-device combination product candidate (AER-901) for the treatment of PAH in mainland China, Hong Kong, Macau, and Taiwan. Furthermore, The World Bank Group reported that the current healthcare expenditure of China grew from 4.94% of the total GDP in 2015 to 5.35% in 2019, which is boosting drug development in the country. Hence, the high prevalence of PAH, a rise in healthcare expenditure, and advancements by key players are expected to propel the growth of the pulmonary arterial hypertension market in China.

Asia Pacific Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Billion)

Asia Pacific Pulmonary Arterial Hypertension Market Segmentation

The Asia Pacific pulmonary arterial hypertension market is segmented on the basis of drugs, type, route of administration, distribution channel, and country.

Based on drugs, the Asia Pacific pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2022, the prostacyclin and prostacyclin analogs segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Based on type, the Asia Pacific pulmonary arterial hypertension market is bifurcated into branded and generics. In 2022, the branded segment registered a larger share in the Asia Pacific pulmonary arterial hypertension market.

Based on route of administration, the Asia Pacific pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. In 2022, the oral segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Based on distribution channel, the Asia Pacific pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. In 2022, the hospital pharmacies and clinics segment registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Based on country, the Asia Pacific pulmonary arterial hypertension market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2022, China registered the largest share in the Asia Pacific pulmonary arterial hypertension market.

Bayer AG, Gilead Sciences Inc, GSK Plc, Johnson & Johnson, Lupin Ltd, Novartis AG, Pfizer Inc, and Teva Pharmaceutical Industries Ltd are the leading companies operating in the Asia Pacific pulmonary arterial hypertension market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific pulmonary arterial hypertension market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the pulmonary arterial hypertension market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution